Start reading about ketamine treatment for depression and you notice the same words describing very different arrangements. One page shows a reclining chair, a blood pressure cuff, and a nurse. The next shows a package on a front porch. Both say "ketamine therapy."

This explainer separates the three delivery models, because the differences are not cosmetic. They involve different medications, different legal footing, and different amounts of supervision.

People already hold preferences here, even before they understand the distinctions. Our June 2026 survey, answered by 443 adults across ten Midwest states, found 44 percent preferring to receive this therapy in person at a clinic, with at-home telehealth drawing 22 percent and a start-in-clinic, move-home-later route 23 percent and 11 percent unbothered either way. The figures are final.

Model one: supervised treatment in a certified setting

The clearest version involves esketamine, marketed as Spravato. The FDA cleared it for treatment-resistant depression, which in plain terms means depression that stayed put through fair trials of other antidepressants. The patient sprays it themselves, but only inside a certified health care setting, and then stays to be observed. For a view from the patient's chair, Brain Recovery Centers offers a walk-through of its Spravato visits.

The observation period is not a formality. It exists because of how the medication affects people in the hours after a dose, which is also why patients are told not to drive until the next day. A companion or ride is part of the plan, not a courtesy.

Some clinics instead give intravenous generic ketamine on site. That is off label for depression, though it is still delivered under direct observation. When comparing clinics, ask which of the two a practice provides; the answer affects everything from approval to what a plan may consider.

Model two: at-home telehealth prescribing

Here a person completes a video or questionnaire visit with a clinician, who prescribes generic ketamine, most often a troche or tablet that melts under the tongue, sent by mail. Doses are taken at home.

Several things are true at once. It is legal. It is off label for mood, not an FDA-approved use. Some clinicians in this space are careful and thorough; some operations are thin. Screening depth, whether anyone is reachable during a dose, how a worsening patient is handled, and what happens when treatment fails all vary, with no single standard binding them.

The appeal is real. For someone whose depression makes leaving the house hard, or who lives far from any clinic, removing travel removes the main barrier to starting. That benefit explains why 22 percent of respondents chose it. What the model shifts is responsibility: monitoring clinic staff would otherwise do falls to whoever is in the house, and medication that would stay at a clinic is stored in a home that may hold other people.

Model three: the hybrid

Start supervised, then continue at home once treatment is tolerated and a response appears. It edged pure telehealth, 23 percent to 22, and it is the arrangement people tend to land on when they reason aloud rather than pick from a list.

The logic is sound: the unknown period is the beginning, so put professional attention there. The weak spot is the handoff. If the clinic and the ongoing prescriber are separate organizations, the transition needs agreed criteria and records that actually move. Ask who owns the patient during that gap, because an unowned gap is where care fails.

How to tell which one a website is selling

  • Which medication is it, esketamine or generic ketamine, and in what form?
  • Is it being used for an FDA-approved indication, or off label?
  • Where does the dose happen, and who is physically present?
  • Who is responsible for me between doses, and how do I reach them?

A provider who answers those four plainly is being straight with you. One who answers with adjectives is not.

Why most people have no idea any of this exists

Asked directly, 73 percent of respondents could not recall ever hearing of Spravato; a further 21 percent had the name without any sense of the drug, leaving 6 percent who could explain it. So the delivery preference above is mostly instinct, not comparison shopping, and many people meet this category through an ad, a poor place to learn the difference between an approved, supervised treatment and an off-label prescription in the mail.

The practical filters most people apply

Asked what matters most in choosing a provider, respondents put coverage far in front: 85 percent listed insurance in their top two. Nearness came next with 43 percent; FDA approval claimed 27, fast results 24, privacy 11, and a service-member specialty 10.

On FDA approval specifically, 19 percent treated it as decisive and 40 percent as major, 59 percent together, while 27 percent gave it some weight and 14 percent none.

Together those answers describe people who want an established treatment their plan recognizes, delivered reasonably close. All three pull toward the supervised model, whether or not the people expressing them know why.

Where to start if this is new to you

Begin with a clinician who knows your history, as most respondents said they would: 56 percent picked their primary care doctor as a first stop, and a psychiatrist or mental health professional drew 23 percent. Bring a written list of the antidepressants you have tried, how long you took each, and why you stopped. That record decides whether the approved treatment is even a candidate, and every prescriber or insurer will ask for it.

The limits of an explainer

This article describes how treatments are delivered. It does not evaluate them, claims none will help you, and is not medical advice. Ketamine and esketamine involve real considerations, including monitoring and interactions with other conditions and medications, and whether any of it suits you is a clinical judgment for a professional with your full history.

If depression has taken you somewhere frightening, reach out now rather than later. Dial or text 988 for a Lifeline counselor, day or night, even while you are still deciding whether things are bad enough. They would rather hear from you early.

Methodology

The publisher of this site commissioned and financed the study. Pollfish handled fieldwork on its consumer panel, which wrapped up on June 23, 2026; 443 consenting adults aged 18 to 64 in ten Midwest states took part. Where a question permitted several answers, results are percentages of respondents and total more than 100. These figures come from the concluded panel validation.